60 degrees pharmaceuticals, Inc. Financials
This page shows 60 degrees pharmaceuticals, Inc. (SXTP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage economics still depend on fresh financing because higher sales have not yet reduced the company’s underlying cash burn.
FY2025 revenue nearly doubled, yet gross profit stayed near$224K ; that means the extra sales arrived with weaker gross efficiency rather than creating a stronger cash engine. The smaller operating loss mainly reflects R&D spend dropping from$5.0M to$2.1M , so the apparent improvement came more from spending mix than from the business suddenly scaling.
Year-end cash of
This is not primarily a debt-driven story: long-term debt was just
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of 60 degrees pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
60 degrees pharmaceuticals, Inc. has an operating margin of -771.6%, meaning the company retains $-772 of operating profit per $100 of revenue. This below-average margin results in a low score of 3/100, suggesting thin profitability after operating expenses. This is up from -1599.0% the prior year.
60 degrees pharmaceuticals, Inc. carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 85/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.66, 60 degrees pharmaceuticals, Inc. holds $2.66 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 71/100.
While 60 degrees pharmaceuticals, Inc. generated -$6.8M in operating cash flow, capex of $140K consumed most of it, leaving -$7.0M in free cash flow. This results in a low score of 2/100, reflecting heavy capital investment rather than weak cash generation.
60 degrees pharmaceuticals, Inc. generates a -212.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 2/100. This is down from -196.9% the prior year.
60 degrees pharmaceuticals, Inc. scores -15.14, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.1M) relative to total liabilities ($2.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
60 degrees pharmaceuticals, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, 60 degrees pharmaceuticals, Inc. generates $0.93 in operating cash flow (-$6.8M OCF vs -$7.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
60 degrees pharmaceuticals, Inc. earns $-994.1 in operating income for every $1 of interest expense (-$7.8M vs $8K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
60 degrees pharmaceuticals, Inc. generated $1.0M in revenue in fiscal year 2025. This represents an increase of 65.5% from the prior year.
60 degrees pharmaceuticals, Inc.'s EBITDA was -$7.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.5% from the prior year.
60 degrees pharmaceuticals, Inc. reported -$7.4M in net income in fiscal year 2025. This represents an increase of 7.3% from the prior year.
60 degrees pharmaceuticals, Inc. earned $-11.73 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
60 degrees pharmaceuticals, Inc. generated -$7.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 21.5% from the prior year.
60 degrees pharmaceuticals, Inc. held $1.5M in cash against $144K in long-term debt as of fiscal year 2025.
60 degrees pharmaceuticals, Inc. had 1M shares outstanding in fiscal year 2025.
Margins & Returns
60 degrees pharmaceuticals, Inc.'s gross margin was 22.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 14.4 percentage points from the prior year.
60 degrees pharmaceuticals, Inc.'s operating margin was -771.6% in fiscal year 2025, reflecting core business profitability. This is up 827.4 percentage points from the prior year.
60 degrees pharmaceuticals, Inc.'s net profit margin was -732.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 575.5 percentage points from the prior year.
60 degrees pharmaceuticals, Inc.'s ROE was -212.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 15.7 percentage points from the prior year.
Capital Allocation
60 degrees pharmaceuticals, Inc. invested $2.1M in research and development in fiscal year 2025. This represents a decrease of 57.8% from the prior year.
60 degrees pharmaceuticals, Inc. invested $140K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 34.8% from the prior year.
SXTP Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $162K-46.6% | $303K-30.7% | $438K+333.6% | $101K-38.3% | $164K-32.3% | $242K+78.6% | $135K+8.3% | $125K |
| Cost of Revenue | $86K-29.0% | $121K-77.6% | $538K+974.3% | $50K-31.7% | $73K-37.9% | $118K+5.7% | $112K+24.7% | $90K |
| Gross Profit | $76K-58.2% | $183K+282.5% | -$100K-296.7% | $51K-43.6% | $90K-26.9% | $124K+423.4% | $24K-33.3% | $35K |
| R&D Expenses | $281K-58.3% | $676K-16.6% | $810K+224.1% | $250K-32.6% | $371K-39.6% | $614K-34.7% | $940K-69.6% | $3.1M |
| SG&A Expenses | $1.9M+31.5% | $1.4M-4.6% | $1.5M-6.6% | $1.6M-6.4% | $1.7M+7.3% | $1.6M+32.1% | $1.2M+7.6% | $1.1M |
| Operating Income | -$2.1M-9.3% | -$1.9M+17.6% | -$2.3M-44.9% | -$1.6M+16.0% | -$1.9M+7.5% | -$2.1M+2.5% | -$2.1M+49.4% | -$4.2M |
| Interest Expense | $1K-55.0% | $3K+80.7% | $2K+39.9% | $1K-31.8% | $2K+227.7% | -$1K | $0 | $0 |
| Income Tax | N/A | -$2K-825.2% | $250-83.3% | $2K+2281.0% | $63+108.4% | -$751-400.4% | $250-42.9% | $438 |
| Net Income | -$2.1M-45.2% | -$1.4M+37.9% | -$2.3M-33.6% | -$1.7M+7.6% | -$1.9M+8.2% | -$2.0M+5.3% | -$2.2M+48.2% | -$4.2M |
| EPS (Diluted) | $-1.28 | N/A | $-0.66+47.2% | $-1.25+80.0% | $-6.25 | N/A | $-2.92+86.2% | $-21.12 |
SXTP Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.8M+26.0% | $5.4M-19.8% | $6.7M+60.0% | $4.2M-30.0% | $6.0M+3.8% | $5.8M-22.4% | $7.4M+71.5% | $4.3M |
| Current Assets | $6.3M+27.9% | $4.9M-22.4% | $6.3M+64.1% | $3.8M-32.0% | $5.7M+4.9% | $5.4M-21.8% | $6.9M+83.1% | $3.8M |
| Cash & Equivalents | $3.3M+121.0% | $1.5M-63.3% | $4.1M+109.2% | $2.0M-43.0% | $3.5M+108.0% | $1.7M-49.7% | $3.3M+109.4% | $1.6M |
| Inventory | $911K+38.6% | $657K+24.7% | $527K-34.1% | $799K+3.4% | $773K+74.6% | $443K-2.1% | $452K+6.1% | $426K |
| Accounts Receivable | $336K-34.1% | $510K-24.4% | $674K+128.5% | $295K-39.6% | $488K+0.3% | $487K+50.3% | $324K+9.3% | $296K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.0M+1.6% | $2.0M-15.2% | $2.3M+27.6% | $1.8M-5.8% | $1.9M+8.0% | $1.8M+23.8% | $1.5M+6.6% | $1.4M |
| Current Liabilities | $1.9M+1.8% | $1.8M-16.1% | $2.2M+30.0% | $1.7M-6.2% | $1.8M+8.8% | $1.7M+26.5% | $1.3M+7.5% | $1.2M |
| Long-Term Debt | $150K+4.2% | $144K-4.0% | $150K0.0% | $150K0.0% | $150K+2.0% | $147K-1.9% | $150K0.0% | $150K |
| Total Equity | $4.8M+39.4% | $3.5M-21.8% | $4.4M+82.4% | $2.4M-40.9% | $4.1M+1.8% | $4.0M-33.2% | $6.0M+99.0% | $3.0M |
| Retained Earnings | -$50.0M-4.4% | -$47.9M-3.1% | -$46.5M-5.2% | -$44.1M-4.1% | -$42.4M-4.6% | -$40.5M-5.3% | -$38.5M-5.9% | -$36.3M |
SXTP Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M-62.0% | -$1.7M+19.8% | -$2.1M-45.4% | -$1.5M+9.2% | -$1.6M+2.5% | -$1.6M+2.6% | -$1.7M-41.5% | -$1.2M |
| Capital Expenditures | $30K-62.4% | $80K+698.9% | $10K-78.9% | $47K+1667.1% | $3K | $0-100.0% | $14K | N/A |
| Free Cash Flow | -$2.8M-56.4% | -$1.8M+16.4% | -$2.1M-41.5% | -$1.5M+6.4% | -$1.6M+2.3% | -$1.6M+3.3% | -$1.7M | N/A |
| Investing Cash Flow | $1.2M+187.1% | -$1.4M-5277.0% | -$25K+50.7% | -$52K-103.0% | $1.7M+81249.6% | -$2K+99.9% | -$1.7M-1237.8% | -$131K |
| Financing Cash Flow | $3.4M+634.8% | $459K-89.3% | $4.3M | $0-100.0% | $1.7M+174298.7% | $973-100.0% | $5.2M+595495.6% | -$865 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SXTP Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.1%-13.1pp | 60.2%+83.1pp | -22.9%-73.3pp | 50.4%-4.8pp | 55.2%+4.1pp | 51.1%+33.7pp | 17.4%-10.9pp | 28.3% |
| Operating Margin | -1292.5%-660.5pp | -632.0%-100.6pp | -531.4%+1058.6pp | -1590.0%-421.6pp | -1168.4%-313.7pp | -854.7%+711.3pp | -1566.0%+1785.7pp | -3351.8% |
| Net Margin | -1288.9%-814.7pp | -474.2%+55.1pp | -529.3%+1188.4pp | -1717.7%-570.4pp | -1147.4%-301.0pp | -846.3%+750.1pp | -1596.4%+1742.6pp | -3338.9% |
| Return on Equity | -43.3%-1.7pp | -41.5%+10.7pp | -52.3%+19.1pp | -71.4%-25.7pp | -45.7%+5.0pp | -50.7%-14.9pp | -35.8%+101.7pp | -137.5% |
| Return on Assets | -30.9%-4.1pp | -26.8%+7.8pp | -34.6%+6.8pp | -41.5%-10.1pp | -31.4%+4.1pp | -35.5%-6.4pp | -29.1%+67.3pp | -96.4% |
| Current Ratio | 3.34+0.7 | 2.66-0.2 | 2.87+0.6 | 2.27-0.9 | 3.13-0.1 | 3.25-2.0 | 5.26+2.2 | 3.09 |
| Debt-to-Equity | 0.03-0.0 | 0.040.0 | 0.03-0.0 | 0.06+0.0 | 0.040.0 | 0.04+0.0 | 0.02-0.0 | 0.05 |
| FCF Margin | -1709.9%-1125.7pp | -584.2%-99.9pp | -484.3%+999.4pp | -1483.6%-505.3pp | -978.3%-300.3pp | -678.0%+574.9pp | -1252.8% | N/A |
Similar Companies
Frequently Asked Questions
What is 60 degrees pharmaceuticals, Inc.'s annual revenue?
60 degrees pharmaceuticals, Inc. (SXTP) reported $1.0M in total revenue for fiscal year 2025. This represents a 65.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is 60 degrees pharmaceuticals, Inc.'s revenue growing?
60 degrees pharmaceuticals, Inc. (SXTP) revenue grew by 65.5% year-over-year, from $608K to $1.0M in fiscal year 2025.
Is 60 degrees pharmaceuticals, Inc. profitable?
No, 60 degrees pharmaceuticals, Inc. (SXTP) reported a net income of -$7.4M in fiscal year 2025, with a net profit margin of -732.5%.
What is 60 degrees pharmaceuticals, Inc.'s EBITDA?
60 degrees pharmaceuticals, Inc. (SXTP) had EBITDA of -$7.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does 60 degrees pharmaceuticals, Inc. have?
As of fiscal year 2025, 60 degrees pharmaceuticals, Inc. (SXTP) had $1.5M in cash and equivalents against $144K in long-term debt.
What is 60 degrees pharmaceuticals, Inc.'s gross margin?
60 degrees pharmaceuticals, Inc. (SXTP) had a gross margin of 22.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is 60 degrees pharmaceuticals, Inc.'s operating margin?
60 degrees pharmaceuticals, Inc. (SXTP) had an operating margin of -771.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is 60 degrees pharmaceuticals, Inc.'s net profit margin?
60 degrees pharmaceuticals, Inc. (SXTP) had a net profit margin of -732.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is 60 degrees pharmaceuticals, Inc.'s return on equity (ROE)?
60 degrees pharmaceuticals, Inc. (SXTP) has a return on equity of -212.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is 60 degrees pharmaceuticals, Inc.'s free cash flow?
60 degrees pharmaceuticals, Inc. (SXTP) generated -$7.0M in free cash flow during fiscal year 2025. This represents a -21.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is 60 degrees pharmaceuticals, Inc.'s operating cash flow?
60 degrees pharmaceuticals, Inc. (SXTP) generated -$6.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are 60 degrees pharmaceuticals, Inc.'s total assets?
60 degrees pharmaceuticals, Inc. (SXTP) had $5.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are 60 degrees pharmaceuticals, Inc.'s capital expenditures?
60 degrees pharmaceuticals, Inc. (SXTP) invested $140K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does 60 degrees pharmaceuticals, Inc. spend on research and development?
60 degrees pharmaceuticals, Inc. (SXTP) invested $2.1M in research and development during fiscal year 2025.
What is 60 degrees pharmaceuticals, Inc.'s current ratio?
60 degrees pharmaceuticals, Inc. (SXTP) had a current ratio of 2.66 as of fiscal year 2025, which is generally considered healthy.
What is 60 degrees pharmaceuticals, Inc.'s debt-to-equity ratio?
60 degrees pharmaceuticals, Inc. (SXTP) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is 60 degrees pharmaceuticals, Inc.'s return on assets (ROA)?
60 degrees pharmaceuticals, Inc. (SXTP) had a return on assets of -137.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is 60 degrees pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2025 data, 60 degrees pharmaceuticals, Inc. (SXTP) had $1.5M in cash against an annual operating cash burn of $6.8M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is 60 degrees pharmaceuticals, Inc.'s Altman Z-Score?
60 degrees pharmaceuticals, Inc. (SXTP) has an Altman Z-Score of -15.14, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is 60 degrees pharmaceuticals, Inc.'s Piotroski F-Score?
60 degrees pharmaceuticals, Inc. (SXTP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are 60 degrees pharmaceuticals, Inc.'s earnings high quality?
60 degrees pharmaceuticals, Inc. (SXTP) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can 60 degrees pharmaceuticals, Inc. cover its interest payments?
60 degrees pharmaceuticals, Inc. (SXTP) has an interest coverage ratio of -994.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is 60 degrees pharmaceuticals, Inc.?
60 degrees pharmaceuticals, Inc. (SXTP) scores 27 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.